The cited alterations are part of a syndrome, defined as chronic kidney disease–mineral bone disorder (CKD-MBD) by the 2006 KDIGO guidelines [5], which can comprise one or more of the following manifestations: abnormalities in calcium, phosphate, parathyroid hormone, or vitamin D metabolism; altered bone volume, mineralization, linear growth, strength, or turnover; extraskeletal calcifications. The gene discussed is PTH; the disease is chronic kidney disease.